Ryoncil
Payments companies reported to CMS as associated with Ryoncil. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ryoncil, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ryoncil
These are the largest totals companies reported as associated with Ryoncil. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Philip Krause | Potomac, MD | Infectious Disease | $346,380.67 |
| Jie Cheng | Houston, TX | Clinical Cardiac Electrophysiology | $60,511.05 |
| Joanne Kurtzberg | Durham, NC | Pediatric Hematology-Oncology | $28,217.69 |
| Michael Rosen | Palo Alto, CA | Pediatric Gastroenterology | $15,200.00 |
| John Levine | New York, NY | Pediatric Hematology-Oncology | $11,867.57 |
| Paul Carpenter | Seattle, WA | Pediatric Hematology-Oncology | $11,160.00 |
| Prakash Satwani | New York, NY | Pediatric Hematology-Oncology | $8,845.17 |
| Andrew Harris | New York, NY | Pediatric Hematology-Oncology | $4,442.97 |
| Marla Dubinsky | New York, NY | $3,700.00 | |
| Michael Verneris | Aurora, CO | Pediatric Hematology-Oncology | $3,262.12 |
Prescribed Ryoncil?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.